Coronary artery disease remains a leading cause of mortality worldwide and is commonly treated with percutaneous coronary intervention (PCI). Typically, PCI is guided by invasive coronary angiography (ICA). However, ICA has inherent limitations in accurately assessing vessel dimensions, calcium burden, circumferential tissue and whether a stent has achieved full expansion. [1] Therefore ICA alone is insufficient for guiding stent optimization, especially in complex lesions which are most vulnerable to long-term stent failure. [2] To overcome the limitations of ICA, intracoronary imaging can be used to guide and optimize PCI. The advantages of intracoronary imaging include obtaining larger lumen areas, better stent expansion and strut apposition, full lesion stent coverage and identifying stent complications. Multiple randomized studies have shown that these advantages translate into a reduction in major adverse cardiovascular events (MACE) in complex PCI. Consequently, the recommendation for intracoronary imaging has been upgraded in the most recent guidelines. [3-6] Despite robust evidence supporting its benefits, intracoronary imaging remains relatively underused in real-world practice and in the Netherlands it is only used in 7% of complex PCI procedures. [7] This underutilization may be attributed to several factors, including operator and hospital-dependent issues such as lack of experience, reluctance to spend additional time on intracoronary imaging and concerns about its cost-effectiveness. [8] Therefore, initiating an implementation project to incorporate intracoronary imaging into routine use in the catheterization lab during complex PCI would be highly valuable. [9] Such a project could make imaging-guided PCI the standard of care in complex PCI. Additionally, it could evaluate the cost-effectiveness of routine intracoronary imaging during complex PCI.
For this reason we designed the OPTIMIZE-PCI II, a national registry-based quality improvement project. This project is aimed at implementing a liberal intracoronary imaging-guided strategy for complex PCI across multiple centres in the Netherlands, with data extraction from the Netherlands Heart Registration (NHR) database. The objective of the OPTIMIZE-PCI II is to establish a routine use of intracoronary imaging in complex PCI, to determine if this approach reduces adverse cardiac events in real-world practice, and evaluate its cost-effectiveness.

开始日期2025-04-01

申办/合作机构

雅培医疗器械贸易（上海）有限公司

[+3]

NCT06595888

/ CompletedN/A

CT 5400 RT System Application Clinical Study

The purpose of this study is to assess the satisfaction of the common functions, the operation convenience, and the whole system stability, and the safety of CT 5400 RT System.

开始日期2025-03-14

申办/合作机构

Philips Clinical & Medical Affairs Global.

[+1]

NCT06860230

/ CompletedN/A

Evaluation of NellcorTM Pulse Oximetry Accuracy With the Philips picoSAT X SpO2 Board With Fourier Artifact Suppression Technology in Adult Volunteers

Evaluation of Philips FAST technology with Nellcor sensors

开始日期2025-03-11

申办/合作机构

Medtronic Plc

[+1]

100 项与 Koninklijke Philips NV 相关的临床结果

登录后查看更多信息

0 项与 Koninklijke Philips NV 相关的专利（医药）

登录后查看更多信息

4,191

项与 Koninklijke Philips NV 相关的文献（医药）

2025-12-31·Computer Assisted Surgery

Deep learning methods for clinical workflow phase-based prediction of procedure duration: a benchmark study

Article

作者: van der Elst, Maarten ; Frassini, Emanuele ; Vijfvinkel, Teddy S. ; Butler, Rick M. ; Hendriks, Benno H. W. ; van den Dobbelsteen, John J.

This study evaluates the performance of deep learning models in the prediction of the end time of procedures performed in the cardiac catheterization laboratory (cath lab). We employed only the clinical phases derived from video analysis as input to the algorithms. Our results show that InceptionTime and LSTM-FCN yielded the most accurate predictions. InceptionTime achieves Mean Absolute Error (MAE) values below 5 min and Symmetric Mean Absolute Percentage Error (SMAPE) under 6% at 60-s sampling intervals. In contrast, LSTM with attention mechanism and standard LSTM models have higher error rates, indicating challenges in handling both long-term and short-term dependencies. CNN-based models, especially InceptionTime, excel at feature extraction across different scales, making them effective for time-series predictions. We also analyzed training and testing times. CNN models, despite higher computational costs, significantly reduce prediction errors. The Transformer model has the fastest inference time, making it ideal for real-time applications. An ensemble model derived by averaging the two best performing algorithms reported low MAE and SMAPE, although needing longer training. Future research should validate these findings across different procedural contexts and explore ways to optimize training times without losing accuracy. Integrating these models into clinical scheduling systems could improve efficiency in cath labs. Our research demonstrates that the models we implemented can form the basis of an automated tool, which predicts the optimal time to call the next patient with an average error of approximately 30 s. These findings show the effectiveness of deep learning models, especially CNN-based architectures, in accurately predicting procedure end times.

2025-10-01·MAGNETIC RESONANCE IMAGING

Imaging of the renal allograft vasculature without gadolinium contrast: Intraindividual comparison between relaxation-enhanced angiography without contrast and triggering (REACT) and 4D contrast-enhanced MR-angiography

Article

作者: Stippel, Dirk ; Gietzen, Carsten ; Tristram, Juliana ; Hummels, Marielle ; Gertz, Roman ; Janssen, Jan Paul ; Persigehl, Thorsten ; Gietzen, Thorsten ; Weiss, Kilian ; Bremm, Johannes ; Kaya, Kenan ; Pennig, Lenhard ; Pennig, Henry

BACKGROUND:

Complications after kidney transplantation include transplant renal artery stenosis (TRAS), which can be assessed using Doppler ultrasonography, computed tomography angiography, and magnetic resonance angiography (MRA). Contrast-enhanced MRA (CE-MRA) has limitations, including potential allergic reactions, limited use in kidney failure, and uncertain long-term effects of gadolinium retention.

PURPOSE:

To evaluate Relaxation-Enhanced Angiography without Contrast and Triggering (REACT), a novel 3D isotropic flow-independent non-CE-MRA pulse sequence, for imaging of the renal allograft vasculature by performing an intraindividual comparison to 4D CE-MRA at 3Tesla.

METHODS:

Forty studies of 39 patients were included in this retrospective, single-centre study. Two board-certified radiologists independently evaluated MRA datasets for TRAS and rated their diagnostic confidence and the image quality of pelvic vessels using 5-point Likert scales (5 = excellent). Apparent signal- and contrast-to-noise ratios (aSNR/aCNR) were measured for arterial and venous graft vessels.

RESULTS:

REACT (median acquisition time 04:33 min [IQR 3:58-5:20 min]) showed 90.0 % sensitivity and 100.0 % specificity for TRAS in almost perfect agreement (r = 0.97) with 4D CE-MRA (03:41 min [3:38-4:46 min], p = 0.001) and similar diagnostic confidence (REACT: 4.0 [4.0-4.0] vs. 4D CE-MRA: 4.0 [3.0-4.0], p = 0.54). Arterial image quality was comparable (4.0 [3.7-4.4] vs. 4.0 [4.0-4.4], p = 0.49) whereas veins yielded higher scores in REACT (3.2 [3.0-3.5] vs. 2.4 [2.0-3.0], p < 0.001). Transplant renal artery (mean ± SD; 44.5 ± 18.2 vs. 45.9 ± 21.0, p = 0.71; 36.3 ± 15.0 vs. 41.0 ± 20.0, p = 0.16) and vein (37.1 ± 19.8 vs. 30.3 ± 15.2, p = 0.06; 29.4 ± 17.1 vs. 25.0 ± 14.7, p = 0.17) showed no difference in aSNR and aCNR.

CONCLUSION:

REACT provides accurate detection of TRAS with image quality comparable to 4D CE-MRA, offering a risk-free alternative for imaging after renal transplantation.

2025-09-01·MAGNETIC RESONANCE IMAGING

Appropriate strength of acceleration selective-motion sensitized gradient for non-triggered, non-contrast enhanced magnetic resonance angiography of the lower extremities

Article

作者: Shibukawa, Shuhei ; Hayashi, Norio ; Miyati, Toshiaki ; Horie, Tomohiko ; Obara, Makoto ; Konta, Natsuo ; Niwa, Tetsu ; Kawamura, Yui

Non-contrast enhanced magnetic resonance angiography (MRA) is useful for diagnosing peripheral arterial disease, especially in patients with renal insufficiency. Recently, non-triggered, non-contrast enhanced MRA using acceleration selective-motion sensitized gradient (AS-MSG), known as enhanced acceleration-selective arterial spin labeling (eAccASL), has been introduced. We aimed to investigate the appropriate strength of the AS-MSG for this technique in the lower extremities. Non-triggered eAccASL with four acceleration encodings (AENCs; 0.17, 0.29, 0.58, and 0.87 m/s²) was compared with electrocardiography (ECG)-triggered eAccASL (AENC: 0.87 m/s²). In the flow phantom, signal intensities (SIs) were calculated. A higher SI was observed with a smaller AENC on non-triggered eAccASL. In eight volunteers, vessel-background contrasts (VBCs) were calculated, and arterial visibility and venous artifacts were assessed by two radiologists. A higher VBC was observed with a smaller AENC on non-triggered eAccASL. The VBCs of non-triggered eAccASL 0.87 were lower than those of ECG-triggered eAccASL 0.87 in the peroneal, and anterior and posterior tibial arteries (all p < 0.05). Subjective scores for arterial visibility did not differ, with median scores within acceptable levels. The venous artifacts score of non-triggered eAccASL 0.17 was lower than those of non-triggered eAccASL 0.29, 0.58, and 0.87 and ECG-triggered eAccASL 0.87 (p < 0.01, p < 0.05, p < 0.001, and p < 0.01, respectively). In two clinical patients, arterial visibility on non-triggered eAccASL 0.29 was comparable or superior to that on ECG-triggered eAccASL 0.87. An AENC of 0.29-0.58 m/s² was considered appropriate for non-triggered, non-contrast enhanced lower-extremity MRA using eAccASL.

1,438

项与 Koninklijke Philips NV 相关的新闻（医药）

2025-08-11

·医药健闻

跨国药企在中国 | 碧迪、诺和诺德、富士胶片、艾昆纬、飞利浦、赛诺菲、卫材、强生、阿斯利康、诺华、波士顿科学、泰利福等新动态

跨国药企在中国重点资讯文 | 苏丁企业动态碧迪医疗碧迪医疗宣布，其首台本土化生产的流式细胞仪BD FACSLyric正式投入批量生产，在碧迪快速诊断产品（苏州）有限公司举办剪彩活动。流式细胞仪BD FACSLyric的本土化战略通过本地化生产全链路构建，使国内医疗及科研机构能够更高效地获取到先进的流式设备，直接提升了临床检验与科研工作的效率。更关键的是，该战略通过全价值链赋能体系的打造，有力地推动了中国流式细胞术创新生态链向高质量发展阶段迈进。诺和诺德诺和诺德CEO齐亚尔·迈克·杜斯特达（Maziar Mike Doustdar）在电话会上回应了投资人关于司美格鲁肽在中国市场上面临的竞争挑战。杜斯特达表示，虽然中国GLP-1糖尿病药出现了下滑，但减重药销售是逐步增长的。他解释称，糖尿病药销量出现下滑是由于经销商库存发生的变化；而去年刚刚获批的司美格鲁肽减重药目前还在放量阶段，尚未进一步下沉到二、三、四线城市。富士胶片8月7-8日，第八届生物药工艺发展大会（BPD）在上海张江科学会堂举办。富士胶片生命科学作为重要参展商亮相，围绕三大核心业务展示旗下最新成果：细胞培养解决方案，包括无血清培养基和细胞培养补充剂；iPSC衍生细胞工具，如人来源iPSC分化的心肌细胞、神经细胞等；实验室试剂与质量控制解决方案。艾昆纬科兴制药与IQVIA艾昆纬达成全面战略合作关系，双方将链接彼此优势资源，共同推进科兴制药创新药和生物类似药在欧洲，乃至全球市场的临床设计、注册与商业化进程。飞利浦国内医疗信息化领域领先企业创业慧康公告，公司第二大股东飞利浦（中国）投资有限公司，计划减持创业慧康股份不超过4633.28万股（含），占剔除公司回购专用账户股份后总股本比例为3%。公开信息显示，飞利浦目前持有该公司股份1.55亿股，占其总股本比例为10.01%，占剔除公司回购专用账户股份后总股本比例为10.04%。德达医疗7月25日，中国红十字基金会生命教育项目办主任陈珞一行赴上海德达医院，看望在此接受治疗的42名来自西藏、新疆的先心病患儿。此次接受治疗的患儿中，19人来自西藏林芝，23人来自新疆喀什地区和巴音郭楞蒙古自治州。他们在中国红十字基金会2025年“天使之旅”新疆、西藏先心病患儿筛查救助活动中，被上海德达心血管医院黄连军、刘建实率领的筛查医疗团队确诊为先心病。经专家确诊符合手术条件的患儿，分批前往德达医院接受治疗。产业动态赛诺菲停止波立达(阿利西尤单抗注射液)在中国市场的供应。对此，赛诺菲方面表示，停供是因为全球供应方面的问题，以及公司在中国心血管产品策略的升级：公司去年年底与箕星药业的Aficamten达成了大中华区BD合作协议，近期也宣布了获得维亚臻在研药物普乐司兰钠注射液大中华区权利，公司在华的心血管产品策略将进行整体升级。赛诺菲方面还强调，将持续提供不同领域的产品，满足国内患者的需求。卫材（中国）药业有限公司宣布，首批创新药物达卫可（通用名：莱博雷生）已抵达中国并顺利完成药品检验流程，并已正式启程发往全国各大医院及指定药店，在北京大学第六医院成功开出全国首方。达卫可在京东健康全网首发。作为中国首个获批上市的双食欲素受体拮抗剂，该药通过精准调节睡眠－觉醒节律，为失眠患者提供全新治疗方案。强生宣布，旗下创新治疗药物锐珂（埃万妥单抗注射液）正式获得国家药品监督管理局批准，联合利珂（甲磺酸兰泽替尼片）适用于携带表皮生长因子受体（EGFR）19号外显子缺失或21号外显子L858R置换突变的局部晚期或转移性非小细胞肺癌（NSCLC）成人患者的一线治疗。此次获批标志着埃万妥单抗在中国迎来了今年第三个肺癌适应症。阿斯利康宣布，其中国首个呼吸生物制剂凡舒卓（英文商品名：Fasenra，通用名：本瑞利珠单抗注射液）新适应症在中国正式批准，用于儿童（6至＜12岁）重度嗜酸粒细胞性哮喘（SEA）的维持治疗。本瑞利珠单抗是精准靶向嗜酸性粒细胞的抗IL-5R生物制剂，此前已在中国获批用于成人和12岁及以上青少年SEA的维持治疗。 CDE官网显示，诺华OAV101注射液申报上市，这是一种基于腺相关病毒（AAV）载体的基因治疗药物，适用于治疗6月龄及以上5q 型脊髓性肌萎缩症（SMA）患者。最初由AveXis公司开发，诺华在2018年以87亿美元收购AveXis公司后获得该产品。华特达因公告，子公司北京达因康健医药有限责任公司与日本诺贝仁制药株式会社签署褪黑素颗粒总经销协议。根据协议，达因康健成为诺贝仁旗下褪黑素颗粒产品（曼乐静）在中国大陆地区（不含港澳台地区）的独家总经销商，负责进口、市场推广及销售。该产品已在中国获批上市，用于改善6-15岁神经发育障碍儿童的入睡困难。合作期限为10年，届满后可续签。波士顿科学公司宣布旗下WATCHMAN FLX Pro带聚偏氟乙烯-六氟丙烯（PVDF-HFP）涂层的左心耳封堵器正式获得国家药品监督管理局批准。该产品适用于具有高卒中风险的非瓣膜性房颤患者，可替代口服抗凝药物治疗预防脑卒中风险。泰利福宣布，其旗下Rüsch EZ-Blocker 一次性使用双侧支气管堵塞器已成功通过中国国家药品监督管理局（NMPA）的严格审评审批，并正式取得医疗器械注册证。此次获批，是泰利福深耕中国市场、满足中国患者医疗需求的又一重要举措。晶泰科技与DoveTree完成总订单规模约470亿港元（59.9亿美元）的管线合作签约，并已收到协议约定的首付款约4亿港元（5100万美元）。根据协议条款，晶泰科技与DoveTree就多款处于临床前阶段的大分子及小分子创新药资产达成合作，并将针对一系列DoveTree指定的靶点进行新药研发，DoveTree独家享有相关药物全球范围的独家开发和商业化权利。除首付款外，晶泰科技还有权获得约3.85亿港元（4900万美元）的进一步付款，以及金额达约462亿港元（58.9亿美元）的潜在里程碑付款及销售分成。乐普生物宣布与Excalipoint就两项临床前T细胞衔接器（TCE）资产的知识产权许可或转让事宜签订协议。Excalipoint将获得在全球范围内开发及商业化目标产品的独家权利。乐普生物将收取总计1,000万美元现金的首付款；通过全资子公司Innocube获得Excalipoint Cayman扩大后股本的10%普通股；总计最高8.475亿美元之开发及商业化里程碑现金付款。本次交易涉及的两款临床前资产是乐普生物基于其自有的TCE平台——TOPAbody平台开发的新一代TCE分子，其中CTM012已获IND批准，另一款为CTM013。京新药业与Gedeon Richter Plc. 签署《专利许可协议》。Gedeon Richter将授予公司一项专利独占许可，公司可在许可区域（中国大陆）内使用该专利开发、制造和商业化盐酸卡利拉嗪制剂及原料药（API）。盐酸卡利拉嗪为非典型抗精神病药物，属于多巴胺D2、D3受体部分激动剂。联系美通社 +86-10-5953 9500 info@prnasia.com

生物类似药并购

2025-08-04

·EINPresswire

FDA issues most serious recall for certain ventilators

The Food and Drug Administration has identified a Class I recall of Philips Respironics V30, A30 and A40 ventilators due to the potential for serious injury or death. The company is updating use instructions due to the risk of failure in the ventilator inoperative alarm, which can cause therapy interruption or loss. The recall involves correcting the devices and does not call for removing them from where they are used or sold. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

2025-08-04

·医药健闻

跨国药企在中国 | 阿斯利康、天境生物、飞利浦、诺华、住友制药、大冢、赛诺菲、西门子医疗、百时美施贵宝、礼来、强生等新动态

跨国药企在中国重点资讯文 | 苏丁企业动态阿斯利康阿斯利康中国总经理、阿斯利康中国生物制药业务总经理林骁向员工宣布，正式成立呼吸生物制剂及自体免疫事业部、呼吸吸入事业部两大事业部，同时完成相关负责人任命。呼吸生物制剂及自体免疫事业部，聚焦高潜力的生物制剂及自体免疫产品管线。呼吸吸入事业部负责倍择瑞、信必可和百沃平产品线。张慧中（Sophie Zhang）7月29日加入阿斯利康中国，担任阿斯利康中国助理副总裁、呼吸生物制剂及自体免疫事业部负责人；童沁杰（William Tong）被任命为阿斯利康中国助理副总裁、呼吸吸入事业部负责人。此外，阿斯利康还宣布晋升李白杨为中国助理副总裁、零售业务负责人。天境生物云顶新耀宣布将向I-Mab（天境生物）投资3090万美元。交易完成后，加上此前已持有的I-Mab股份，云顶新耀将合计持有I-Mab约16.1%的股份，一跃成为其第一大股东。I-Mab是一家总部位于美国的全球性生物技术公司，于美国纳斯达克全球市场挂牌上市，专注开发用于癌症治疗的精准肿瘤免疫药物。飞利浦飞利浦因在循环经济领域的长期投入，荣膺《2025医健可持续创新案例推荐榜》“ESG创新实践”上榜企业。该榜单由第一财经、健闻咨询和上海现代服务业联合会医疗服务专业委员会共同发起。飞利浦的循环经济战略从2012年持续至今，涵盖从生态设计、绿色制造与供应链管理，到产品交付、使用与回收阶段的全周期循环性管理。截至2024年，飞利浦的所有新产品均符合生态设计要求。截至2024年底，飞利浦保持运营层面碳中和，运营废物再利用率94%，并实现所有工厂废弃物零填埋。诺华由诺华发起的“川西南林业碳汇、社区和生物多样性应对气候变化项目”荣获《南方周末》“2025年度ESG创新案例奖”，这也是该项目继本月初被生态环境部评为“2025年企业ESG优秀案例”后，再次成为ESG（环境、社会与治理）领域的标杆案例。与此同时，诺华也在《南方周末》2025年企业社会责任调研中表现优异。诺华还积极推动“气候变化行动计划”，致力于到2040年实现整个价值链的完全“净零排放”，并尽量减少对地球自然资源的使用。住友制药住友制药日本总部7月31日宣布，包括中国区在内的亚洲业务，已于当日完成向丸红集团的股权转让手续。住友制药表示，上述公司分割及股份转让已于2025年7月31日完成，住友制药（中国）有限公司及住友制药亚太公司（Sumitomo Pharma Asia Pacific Pte. Ltd., SMPAP）不再是住友制药的合并子公司。大冢微创医疗公告，Otsuka MedicalDevices Co.， Ltd.（大冢）同意出售约2.91亿股微创医疗股份，买方包括上海上实资本管理有限公司旗下基金、微创医疗一名主要股东We'Tron及公司管理层的投资平台。自2013年以来，大冢持续控股微创医疗，为该公司第一大股东。交易前，其持股比例为20.7%。出售上述股权后，大冢持股比例将降至4.99%。We'Tron（中国微创投资管理有限公司）将成为第一大股东。MICRON泰格医药公告，公司全资附属公司株式会社泰格医药日本与日本MICRON/株式会社マイクロン原股东签署《股份转让协议》，购买其持有的MICRON56.37%股权，合计购买价格为4.84亿日元，折合人民币2347.71万元。本次转让完成后，日本泰格将持有MICRON56.37%股权。本次交易有利于公司进一步深度拓展在日本及亚太地区的业务布局，同时增强在医学影象和临床服务领域的综合竞争。鹏瑞利中国（上海）自由贸易试验区管理委员会陆家嘴管理局、上海陆家嘴（集团）有限公司和新加坡鹏瑞利集团达成战略合作协议，鹏瑞利集团宣布在陆家嘴地区设立外资医疗投资公司，打造上海首家外商独资三级综合医院——上海鹏瑞利医院。上海鹏瑞利医院规划500张床位，投资5亿元，除设置常规内科、外科、体检科等科室以外，重点打造骨科、肿瘤防治、心血管疾病及耳鼻喉等特色诊疗中心。医院将配置一系列国际领先的医疗设备设施。产业动态赛诺菲宣布与Arrowhead的子公司维亚臻签署资产购买协议。维亚臻目前在大中华区开发和商业化Arrowhead的四种在研心血管代谢候选药物。根据协议，赛诺菲将获得在大中华区开发和商业化在研药物普乐司兰钠注射液（Plozasiran）的权利。普乐司兰钠注射液是Arrowhead同类首创的RNA干扰（RNAi）治疗候选药物。资产购买协议交割后，维亚臻将获得赛诺菲1.3亿美元的预付款，并将有资格在普乐司兰钠注射液在中国大陆的各种适应症获批后获得至多2.65亿美元的额外里程碑付款。Arrowhead可获得普乐司兰钠注射液在大中华区产品净销售额的特许权使用费。石药集团发布公告，宣布与美国生物制药公司Madrigal Pharmaceuticals达成重磅授权协议，将其口服GLP-1受体激动剂SYH2086的全球开发、生产及商业化权益授予后者，交易总价值最高可达20.75亿美元。石药集团将获得1.2亿美元预付款，以及最高19.55亿美元的开发、监管及商业里程碑付款。此外，公司还将基于SYH2086年度净销售额收取高达双位数的销售提成。SYH2086目前仍处于临床前阶段，是石药集团自主开发的新型口服小分子GLP-1受体激动剂。国家药品监督管理局正式批准西门子医疗有限公司的“磁共振成像系统”创新产品注册申请。此次获批的7T磁共振成像系统，由7T超导磁体、梯度系统、射频系统等核心部件组成，创新性地采用深度学习技术，在传统7T高场磁共振基础上增加了静动态多通道发射平台与多核成像功能。该系统可提供头部钠图像、四肢肌肉和肝脏的磷核波谱数据，实现对细胞代谢水平的精准监测。百时美施贵宝宣布，欧狄沃（纳武利尤单抗注射液）联合逸沃（伊匹木单抗注射液）方案获得中国国家药品监督管理局（NMPA）批准，适用于由国家药品监督管理局批准的检测评估为PD-L1肿瘤比例分数（TPS）≥1%的表皮生长因子受体（EGFR）基因突变阴性和间变性淋巴瘤激酶（ALK）阴性的转移性非小细胞肺癌一线治疗，成为中国首个获批的肺癌双免疫联合疗法。礼来宣布穆峰达（替尔泊肽注射液）获得中国国家药品监督管理局（NMPA）批准，新增适应症：用于在饮食控制和运动基础上，联合胰岛素（伴或不伴口服降糖药）治疗，改善成人2型糖尿病（T2DM）患者的血糖控制。阿斯利康与默沙东联合宣布其PARP抑制剂利普卓（英文商品名：Lynparza，中文通用名：奥拉帕利片）联合阿比特龙和泼尼松或泼尼松龙在华获批，用于携带胚系或体细胞BRCA突变（gBRCAm或sBRCAm）的转移性去势抵抗性前列腺癌（mCRPC）成人患者的治疗。阿斯利康宣布，伟立瑞（Ultomiris，通用名：瑞利珠单抗注射液）在中国正式获批用于治疗抗水通道蛋白4（AQP4）抗体阳性的成人视神经脊髓炎谱系疾病（NMOSD）患者。NMOSD是一种罕见的、高致残的自身免疫性疾病，主要累及中枢神经系统，特别是脊髓和视神经。NMOSD是瑞利珠单抗在半年内中国获批的第二项适应症。强生第三代EGFR-TKI“兰泽替尼”在国内获批上市。根据公开资料及既往临床研究，推测该适应症为联用埃万妥单抗一线治疗 EGFR 突变局部晚期或转移性NSCLC。联系美通社+86-10-5953 9500info@prnasia.com

高管变更

100 项与 Koninklijke Philips NV 相关的药物交易

登录后查看更多信息

100 项与 Koninklijke Philips NV 相关的转化医学

登录后查看更多信息